Name | Number of supported studies | Average coverage | |
---|---|---|---|
CD8-positive, alpha-beta T cell | 5 studies | 18% ± 2% | |
B cell | 3 studies | 17% ± 2% | |
CD4-positive, alpha-beta T cell | 3 studies | 21% ± 2% | |
exhausted T cell | 3 studies | 23% ± 9% | |
hematopoietic precursor cell | 3 studies | 22% ± 6% | |
epithelial cell | 3 studies | 24% ± 7% | |
GABAergic neuron | 3 studies | 16% ± 1% | |
glutamatergic neuron | 3 studies | 23% ± 3% | |
dendritic cell | 3 studies | 26% ± 6% | |
natural killer cell | 3 studies | 21% ± 2% |
Insufficient scRNA-seq data for expression of EXOSC9 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 100% | 1583.41 | 459 / 459 | 100% | 17.06 | 1118 / 1118 |
esophagus | 100% | 1177.84 | 1445 / 1445 | 100% | 14.22 | 183 / 183 |
uterus | 100% | 1711.63 | 170 / 170 | 100% | 22.18 | 459 / 459 |
lung | 100% | 1377.56 | 577 / 578 | 100% | 14.44 | 1155 / 1155 |
prostate | 100% | 1170.04 | 245 / 245 | 100% | 12.09 | 501 / 502 |
thymus | 100% | 1241.29 | 653 / 653 | 100% | 15.09 | 603 / 605 |
stomach | 100% | 1011.23 | 359 / 359 | 100% | 13.14 | 285 / 286 |
bladder | 100% | 1120.67 | 21 / 21 | 100% | 16.62 | 502 / 504 |
ovary | 100% | 1573.70 | 180 / 180 | 100% | 10.74 | 428 / 430 |
intestine | 100% | 1318.69 | 966 / 966 | 99% | 14.17 | 523 / 527 |
skin | 100% | 1966.10 | 1809 / 1809 | 99% | 19.37 | 468 / 472 |
kidney | 100% | 946.11 | 89 / 89 | 99% | 11.40 | 891 / 901 |
adrenal gland | 100% | 1185.65 | 258 / 258 | 99% | 14.92 | 227 / 230 |
liver | 99% | 583.68 | 224 / 226 | 99% | 9.46 | 402 / 406 |
brain | 98% | 1021.81 | 2592 / 2642 | 100% | 15.19 | 705 / 705 |
pancreas | 99% | 720.38 | 325 / 328 | 99% | 12.34 | 176 / 178 |
adipose | 100% | 1446.97 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 28.19 | 29 / 29 |
spleen | 100% | 1955.12 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 21.99 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 10.24 | 1 / 1 |
blood vessel | 100% | 1205.36 | 1334 / 1335 | 0% | 0 | 0 / 0 |
muscle | 99% | 903.61 | 798 / 803 | 0% | 0 | 0 / 0 |
heart | 98% | 818.11 | 844 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 90% | 9.10 | 72 / 80 |
peripheral blood | 90% | 1422.10 | 834 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0071038 | Biological process | TRAMP-dependent tRNA surveillance pathway |
GO_0006402 | Biological process | mRNA catabolic process |
GO_0071035 | Biological process | nuclear polyadenylation-dependent rRNA catabolic process |
GO_0030307 | Biological process | positive regulation of cell growth |
GO_0006396 | Biological process | RNA processing |
GO_0034475 | Biological process | U4 snRNA 3'-end processing |
GO_0006401 | Biological process | RNA catabolic process |
GO_0034473 | Biological process | U1 snRNA 3'-end processing |
GO_0006955 | Biological process | immune response |
GO_0034476 | Biological process | U5 snRNA 3'-end processing |
GO_0071028 | Biological process | nuclear mRNA surveillance |
GO_0000288 | Biological process | nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay |
GO_0000956 | Biological process | nuclear-transcribed mRNA catabolic process |
GO_0006364 | Biological process | rRNA processing |
GO_0000467 | Biological process | exonucleolytic trimming to generate mature 3'-end of 5.8S rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) |
GO_0005730 | Cellular component | nucleolus |
GO_0000178 | Cellular component | exosome (RNase complex) |
GO_0000228 | Cellular component | nuclear chromosome |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005654 | Cellular component | nucleoplasm |
GO_0000177 | Cellular component | cytoplasmic exosome (RNase complex) |
GO_0101019 | Cellular component | nucleolar exosome (RNase complex) |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0000176 | Cellular component | nuclear exosome (RNase complex) |
GO_0005634 | Cellular component | nucleus |
GO_0004532 | Molecular function | RNA exonuclease activity |
GO_0061629 | Molecular function | RNA polymerase II-specific DNA-binding transcription factor binding |
GO_0035925 | Molecular function | mRNA 3'-UTR AU-rich region binding |
GO_0003723 | Molecular function | RNA binding |
GO_0000175 | Molecular function | 3'-5'-RNA exonuclease activity |
GO_0005515 | Molecular function | protein binding |
Gene name | EXOSC9 |
Protein name | Exosome complex component RRP45 (Exosome component 9) Exosome complex component RRP45 (Autoantigen PM/Scl 1) (Exosome component 9) (P75 polymyositis-scleroderma overlap syndrome-associated autoantigen) (Polymyositis/scleroderma autoantigen 1) (Polymyositis/scleroderma autoantigen 75 kDa) (PM/Scl-75) Exosome component 9 |
Synonyms | hCG_38830 PMSCL1 |
Description | FUNCTION: Non-catalytic component of the RNA exosome complex which has 3'->5' exoribonuclease activity and participates in a multitude of cellular RNA processing and degradation events. In the nucleus, the RNA exosome complex is involved in proper maturation of stable RNA species such as rRNA, snRNA and snoRNA, in the elimination of RNA processing by-products and non-coding 'pervasive' transcripts, such as antisense RNA species and promoter-upstream transcripts (PROMPTs), and of mRNAs with processing defects, thereby limiting or excluding their export to the cytoplasm. The RNA exosome may be involved in Ig class switch recombination (CSR) and/or Ig variable region somatic hypermutation (SHM) by targeting AICDA deamination activity to transcribed dsDNA substrates. In the cytoplasm, the RNA exosome complex is involved in general mRNA turnover and specifically degrades inherently unstable mRNAs containing AU-rich elements (AREs) within their 3' untranslated regions, and in RNA surveillance pathways, preventing translation of aberrant mRNAs. It seems to be involved in degradation of histone mRNA. The catalytic inactive RNA exosome core complex of 9 subunits (Exo-9) is proposed to play a pivotal role in the binding and presentation of RNA for ribonucleolysis, and to serve as a scaffold for the association with catalytic subunits and accessory proteins or complexes. EXOSC9 binds to ARE-containing RNAs. . |
Accessions | ENST00000512454.5 ENST00000513654.5 ENST00000379663.7 [Q06265-2] ENST00000511132.1 D6RIY6 A5PLM5 Q06265 D6R905 D6RA17 D6RAP4 ENST00000243498.10 [Q06265-1] ENST00000511454.5 H0Y9L5 ENST00000509800.5 |